News

Mar 14, 2016

Lyra Self-Retaining Support (SRS) Technology For Pelvic Organ Prolapse (POP) Treatment Is Strengthened By A Newly Issued Patent

Deployable pelvic implant design and several frame-sheet harnessing methods offer an easier and safer implant deployment and surgical procedure

Kerem-Maharal, Israel, March 14th, 2016 – Lyra Medical, a developer of safe and easy POP trans-vaginal implant procedure, filed a new provisional patent to the United States Patent & Trademark Office, covering the company’s Self-Retaining Support technology and recent improvements.

Lyra sees major importance in securing and managing its intellectual property (IP) and protects its IP primarily through patent submission as well as by other means. Two patents titled: “Pelvic implant with anchoring frame” have been approved in the US (Patents No. 7981024, 8920302) and in Europe (Europe Patent No. 1684663). The patents portfolio is managed by “Ehrlich and Partners” an experienced and well respected patent office in Israel.

Lyra evaluates its IP portfolio on an ongoing basis, and additional patent applications are expected to be submitted throughout the development process.

The first issued patent (US 7,981,024) which has been granted by the USPTO on July 19th, 2011, covers the initial pelvic implant with anchoring frame concept, later named after it’s fundamental technology, the SRS (Self-Retaining Support). Lyra Medical has also been granted this patent by the European Patent Office.

 

Lyra Medical’s implant is a revolutionary surgical treatment for women suffering from advanced anterior vaginal wall prolapse with or without apical prolapse. The Self-Retaining Support (SRS) technology eliminates the need for complex anchoring techniques delivering a safe and long-term treatment solution.

 

Lyra's technology mimics the physiologic pubocervical fascia and restores pelvic organs to their anatomical and functional location. This anchorless technique restores transvaginal implants as a viable, safe and effective treatment that far surpasses current mesh kits, sacrocolpopexy and native-tissue repair procedures.

 

 

 “We believe that the future of Pelvic Organ Prolapse treatment depends on eliminating the need for complex anchoring techniques which has been shown to be the main cause of complications in current trans-vaginal techniques. Lyra's technology mimics the physiologic pubocervical fascia and restores pelvic organs to their anatomical and functional location. Recent clinical experience with the SRS implant demonstrated that this anchorless technique could restore transvaginal implants as a viable, safe and effective treatment that far surpasses current mesh kits, sacrocolpopexy and native-tissue repair procedures,” said Iram Levit, Lyra Medical’s CEO

For more information about Lyra Medical and its technology please visit www.lyramed.com .

 

About Lyra Medical

Lyra Medical was established in 2011 by a team of seasoned medical device entrepreneurs to develop a new and safer organ support implant for women suffering from pelvic organ prolapse (POP).

The company’s Self-Retaining Support (SRS) technology is presently being applied in the flagship Lyra system for anterior vaginal wall, Apex and uterine prolapse. The support platform may be applicable in other pelvic organ disorder conditions, such as rectocele and urinary incontinence, as well as other clinical areas. In all these areas, there is an acute need for therapeutic solutions that deliver exceptional safety and long-term efficacy.

Back